Annette Logan-Parker: A Hemophilia B Breakthrough – From Weekly Infusions to One Treatment
Annette Logan-Parker, Founder and Chief Advocacy and Innovation Officer at Cure 4 The Kids Foundation, Innovation Council Member at Coalition Against Childhood Cancer (CAC2), shared on LinkedIn:
”He flew from Arizona to Las Vegas for a single infusion…and never needed another one.
For 39 years, this patient lived with hemophilia B.
That meant intravenous infusions of clotting factor every week, sometimes multiple times a week, just to prevent a bleed that could put him in the hospital.
Every week. For nearly four decades. That was his life.
In 2024, he came to our clinic and received Hemgenix (an FDA-approved gene therapy that delivers a working copy of the gene his body was missing).
One infusion. One afternoon.
More than a year later, his body is producing its own clotting factor. No more weekly treatments. No more planning his entire life around his next infusion.
Cure 4 The Kids Foundation was the first center in Nevada to administer this therapy, and one of only a handful on the entire West Coast.
This is what research looks like when it reaches the bedside. And it’s why Research Recognition Week matters.
Read the full story on our blog, including what families need to know about gene therapy, who’s eligible, and what’s coming next.”
Stay updated with Hemostasis Today.
-
Mar 11, 2026, 18:27Cesar Garrido and Lackram Bodoe Are Advancing WFH Partnerships in Trinidad and Tobago
-
Mar 11, 2026, 18:14Aloke Finn: Silent Plaque Rupture and Healing in Coronary Artery Disease
-
Mar 11, 2026, 17:23Mattia Galli: A Privilege to Collaborate on Such a Complex Topic as Cardio-Rheumatology
-
Mar 11, 2026, 17:12Shubham Misra: Proteomic Biomarkers for Acute Stroke Subtype Classification
-
Mar 11, 2026, 16:55Melanie Daniel: Modeling High-Purity von Willebrand Factor for Individualized Dosing in Surgery
-
Mar 11, 2026, 15:46Bleeding and Thrombosis Outcomes in Older Patients With Myelodysplastic Syndromes – JTH
-
Mar 11, 2026, 15:37Sonia Muliyil: The Greatest Benefit is The Wellbeing and Sustenance of Half The World’s Population
-
Mar 11, 2026, 15:34Kymentie Ferdinande: Rivaroxaban in Cirrhosis and the Path Toward Individualized Anticoagulation
-
Mar 11, 2026, 15:34Sheharyar Raza: When More Testing Isn’t Always Better in Healthy Donor Screening